Oncological Dermatology in Verona

Prevention, early diagnosis, and treatment of skin cancer

Why oncological dermatology is essential

Oncology dermatology in Verona focuses on the early diagnosis and treatment of skin cancers, among the most common diseases. Early intervention improves the prognosis and reduces the risk of complications.


At Dr. Pasquale Adilardi's practice, each patient is treated with a multidisciplinary and personalized approach, based on the most modern scientific evidence.

Italian Melanoma Intergroup IMI

https://www.melanomaimi.it/trova-i-soci-imi/veneto/1268-adilardi-pasquale.html


European Association of Dermato-Oncology (EADO)

https://eado.org/

Early diagnosis, prevention and treatment

Early diagnosis is the most important factor in the treatment of skin cancer, particularly melanoma.

Prevention in dermatology is essential for protecting skin health, preventing skin cancer, and diagnosing numerous dermatological diseases early. Regular dermatological checkups allow for the early detection of suspicious lesions, melanomas, and other skin conditions before they can progress to more serious conditions.

Multidisciplinary Team

For the management of skin melanomas, the dermatology department works closely with the Oncology and Plastic Surgery Unit, ensuring a comprehensive treatment plan that includes:

  • Surgical removal

  • Dermatological and oncological follow-up

  • Periodic checks with digital epiluminescence

    • Book a mole check

    Dermatosurgery: main treatment

    Dermatosurgery is the most effective treatment for most skin cancers.

    • correct some skin aesthetic problems.

    The procedures are generally performed under local anesthesia and on an outpatient basis.


    1. complete removal of the lesion with safety margins
    2. possibility of histological examination for certain diagnosis
    3. interventions often performed on an outpatient basis
    4. Surgical interventions performed on an inpatient basis where necessary


    In the case of melanoma, early treatment guarantees very high cure rates.

    Request an evaluation

    Main skin cancers:

    OncoDermoChirurgia

    1. Basal Cell Carcinoma

    The most common, slow-growing and rarely metastatic.

    Basal cell carcinoma is the most common skin cancer and arises from the basal cells of the epidermis, the outermost layer of the skin. It is a slow-growing malignant skin tumor that, in most cases, is diagnosed early and treated successfully.

    2. Carcinoma squamocellulare

    More aggressive, it can evolve if not treated promptly.

    Squamous cell carcinoma is a malignant skin tumor that originates from the squamous cells of the epidermis. It is one of the most common skin cancers after basal cell carcinoma and can develop especially in areas with high sun exposure.

    Unlike other slow-growing skin cancers, squamous cell carcinoma can be more aggressive and, if not treated early, can invade deep tissue and in some cases spread to other organs.


    3. Melanoma

    Cutaneous melanoma is one of the most aggressive skin cancers and originates from melanocytes, the cells responsible for producing melanin. Although it accounts for a lower percentage than other skin cancers, melanoma is responsible for the majority of skin cancer-related deaths.

    Early diagnosis is essential because melanoma detected in the early stages can be treated with a high chance of recovery.


    ABCDE rule:

    • Asymmetry
    • Irregular edges
    • Non-uniform color
    • Diameter > 6 mm
    • Evolution
    Check your moles

    Advanced diagnosis and tools

    For an accurate evaluation we use:

    • dermatoscopia
    • digital videodermatoscopy
    • skin biopsy
    • histological and immunohistochemical examination

    These tools allow us to precisely define the nature of the lesion and the most appropriate treatment.

    Treatments and Therapies

    Key options include:

    • dermatological surgery
    • photodynamic therapy
    • topical treatments
    • immunoterapia e target therapy
    • Precision Oncology (ONCOGENOME)

    

    Edited by Dr. Adilardi MD Ph.D.

    Oncogenoma Precision Oncology

    Ipilimumab is a monoclonal antibody belonging to the class of immune checkpoint inhibitors, used in the treatment of various malignancies, particularly metastatic or unresectable melanoma. The introduction of this drug represented one of the major innovations in cancer immunotherapy, improving the survival of many patients.

    Ipilimumab works by blocking the protein CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4), a checkpoint molecule present on T lymphocytes that plays a role in limiting the immune response.

    Under physiological conditions, CTLA-4 protects the body from excessive immune system activation. However, tumor cells can exploit this mechanism to evade immune defenses.

    By blocking CTLA-4, Ipilimumab promotes greater activation of T lymphocytes, enhancing the immune system's ability to recognize and fight tumor cells.

    Ipilimumab in the treatment of metastatic melanoma

    Clinical studies published in the New England Journal of Medicine (NEJM) and presented at the American Society of Clinical Oncology (ASCO) have demonstrated that ipilimumab can improve survival in patients with advanced metastatic melanoma, marking a major shift in the therapeutic approach to this disease.

    The research also highlighted that the combination with the experimental gp100 vaccine did not determine a significant clinical benefit compared to the use of ipilimumab alone.

    Immune system activity

    Even in brain metastases, although Ipilimumab does not directly cross the blood-brain barrier, the drug stimulates T lymphocytes, which can also reach brain metastases from melanoma.

    This immunological mechanism has contributed to observing clinical responses in some patients with central nervous system involvement.

    In some cases, the reintroduction of Ipilimumab after a previous therapeutic response has allowed for new disease control, while combination protocols with other immunotherapies, such as interleukin-2 (IL-2), have also been studied.

    Request an evaluation

    Precision Oncology and Oncogenome

    Precision oncology allows us to analyze the genetic characteristics of the tumor to define targeted treatments.

    This approach is particularly useful in cases of melanoma and advanced skin cancers.

    Through the ONCOGENOME project, it is possible to integrate:

    Study of molecular biomarkers

    Personalized therapies

    Advanced disease monitoring

    Second Opinion Dermatological Oncology

    Multidisciplinary Second Opinion for Skin Cancer and Melanoma

    What is the Multidisciplinary Second Opinion for Skin Cancer? It's dedicated to Italian and international patients who wish to obtain a qualified second opinion from a panel of highly experienced specialists.

    The multidisciplinary team includes:

    • Medical oncologists specializing in melanoma and skin cancers;
    • Oncology surgeons;
    • Plastic and reconstructive surgeons;
    • Radiologists specialized in oncological diagnostics.

    This service is intended for patients who have been diagnosed with melanoma, basal cell carcinoma, squamous cell carcinoma, or other forms of skin cancer.

    Subsequently, if necessary, the process can be integrated with in-person specialist visits and personalized treatment programs.

    What is the purpose of a Multidisciplinary Second Opinion for Melanoma and Dermatological Tumors?

    The Multidisciplinary Second Opinion allows you to submit your clinical case to a collegial evaluation by various specialists who collaborate to define the best diagnostic and therapeutic path.

    The goal is:

    • Confirm or deepen the diagnosis;
    • Assess the correct staging of the disease;
    • Analyze available surgical options;
    • Identify the most effective cancer treatments;
    • Evaluate possible reconstructive procedures;
    • Interpret radiological examinations in an integrated manner;
    • Identify access to innovative therapies and precision medicine;
    • Verify eligibility for national and international clinical trials.

    Unlike consulting with a single specialist, a multidisciplinary discussion allows for a comprehensive and shared view of the clinical case, reducing uncertainty and promoting more accurate and personalized treatment decisions.

    The advantages of the Multidisciplinary Second Opinion

    • High-level collegial evaluation: each case is analyzed by a multidisciplinary team that jointly examines all clinical documentation, offering a thorough specialist opinion based on the latest scientific evidence.
    • Access to Precision Oncology: The team is evaluating the potential for molecular and genetic testing to identify targeted therapies and personalized treatments for melanoma and other skin cancers. Access to innovative therapies and clinical trials

    A Multidisciplinary Second Opinion represents a concrete opportunity to obtain an in-depth evaluation of your clinical case and learn about all available treatment options, including the latest innovations in dermatological oncology and precision medicine.


    For more information on skin cancer, melanoma, and available diagnostic and therapeutic options, visit the specialist portal dermatologiaverona.it

    
    oncogenoma.com.


    Request a second opinion